Clinical Trial Update: AZD2014 and Weekly Paclitaxel in Squamous NSCLC [Phase 2]

View source ↗

Summary

A phase 2 trial evaluating AZD2014 in combination with weekly paclitaxel for squamous non-small cell lung cancer has been terminated; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Squamous Non-small Cell Lung Cancer

Drugs mentioned

• AZD2014 (vistusertib)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: AstraZeneca | Conditions: Squamous Non Small Cell Lung Cancer | Phase 2 | Status: TERMINATED | Results posted: 2018-07-03